Five things for pharma marketers to know: Friday, July 21, 2017
1. The FDA plans to study whether companies linking to risk information on character-limiting services like Twitter affects a consumer's retention of risk information, compared to when companies post both risk and benefit information in the initial post.
2. Patients view doctors who have disclosed industry payments as less honest than those that haven't, according to a new study published in the Journal of General Internal Medicine. However, patients did not view physicians who have taken industry payments as less competent. (Journal of General Internal Medicine)
3. Mallinckrodt, which is facing two federal investigations over opioid sales and the pricing of a multiple sclerosis drug, greatly increased the amount of money it gave to House and Senate lawmakers in the first three months of 2017, compared to the same period two years ago. (NYT)
4. Amgen and Novartis said the FDA accepted their application for erenumab, an experimental therapy for migraines. Alder Biopharmaceuticals and Eli Lilly are also developing similar migraine treatments. (Endpoints News)
5. AstraZeneca CEO Pascal Soriot sent out a company-wide memo addressing rumors that he may leave the drugmaker to lead Teva Pharmaceutical Industries, saying that the rumors were part of “everyday business” and he looks forward to working with the staff to see AstraZeneca succeed. (Reuters)